Therapeutic Challenges Continue to Emerge in Myelofibrosis
Published: Wednesday, Aug 28, 2019
James K. McCloskey II, MD
The optimal agents for high-risk and low-risk patients with myelofibrosis have yet to be identified. For low-risk patients, no drug has shown a significant improvement in overall survival; in high-risk disease, standard regimens generate fewer responses as patients typically present with a declining performance status.
... to read the full story